Last edition
News about "PCSK9 inhibitor "
Merck Showcases New Cardio-Pulmonary Data at ACC.26
Merck presented late-breaking data from phase-III and phase-II trials at ACC.26, highlighting advances in its cardio-pulmonary pipeline, including an investigational oral PCSK9 inhibitor and therapies for pulmonary hypertension.
PCSK9 Inhibitor | 17/03/2026 | By News Bureau | 134
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members